v3.25.4
Fair Value Measurements and Financial Instruments - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
May 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Gain (losses) on equity securities still held   $ (39.6) $ (8.6) $ 55.6
Financial Royalty Assets, Current        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Financial royalty asset, percentage of non-controlling interest   7.00% 9.00%  
Financial Royalty Assets, Non-current        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Financial royalty asset, percentage of non-controlling interest   7.00% 8.00%  
Level 3 | Estimate of Fair Value Measurement        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Financing receivables, fair value disclosure, current   $ 900.0 $ 800.0  
Financing receivables, fair value disclosure, non-current   $ 23,400.0 $ 21,400.0  
Level 3 | Measurement Input, Option Volatility        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Measurement input   0.425 0.400  
Cytokinetics        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Long term funding partnership, amount $ 50.0      
Optional additional amount 150.0      
Milestone payments $ 150.0      
Installment repayments, percentage of amount drawn 1.5      
Cytokinetics | Level 3 | Measurement Input, Discount Rate        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Measurement input   0.109 0.111